HC Wainwright Brokers Raise Earnings Estimates for Immunome

Immunome, Inc. (NASDAQ:IMNM) – Investment analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for shares of Immunome in a report issued on Wednesday, March 4th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.53) per share for the quarter, up from their prior forecast of ($0.68). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Immunome’s Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($2.21) EPS, FY2027 earnings at ($1.81) EPS and FY2028 earnings at ($0.54) EPS.

A number of other research analysts also recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Thursday, January 22nd. Truist Financial initiated coverage on shares of Immunome in a report on Monday, December 1st. They issued a “buy” rating and a $36.00 price target on the stock. Stephens lowered their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday. Leerink Partners set a $40.00 target price on shares of Immunome in a research report on Monday, December 15th. Finally, Craig Hallum lifted their price target on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Immunome has a consensus rating of “Moderate Buy” and an average target price of $32.33.

Immunome Stock Up 0.4%

NASDAQ:IMNM opened at $21.04 on Friday. Immunome has a twelve month low of $5.15 and a twelve month high of $27.65. The firm has a market capitalization of $2.38 billion, a P/E ratio of -8.69 and a beta of 2.12. The company has a fifty day moving average of $22.74 and a 200-day moving average of $17.67.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%.

Insider Transactions at Immunome

In other news, CEO Clay B. Siegall purchased 46,511 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was bought at an average price of $21.50 per share, for a total transaction of $999,986.50. Following the purchase, the chief executive officer owned 853,247 shares of the company’s stock, valued at $18,344,810.50. The trade was a 5.77% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Isaac Barchas sold 383,200 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $21.74, for a total value of $8,330,768.00. Following the completion of the sale, the director owned 2,031,181 shares in the company, valued at $44,157,874.94. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders bought 68,518 shares of company stock worth $1,453,958. 7.69% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Assetmark Inc. bought a new stake in Immunome during the 3rd quarter valued at $39,000. BNP Paribas Financial Markets raised its stake in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after purchasing an additional 2,909 shares during the period. Strs Ohio purchased a new stake in Immunome during the 4th quarter worth about $64,000. Tower Research Capital LLC TRC boosted its stake in Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after purchasing an additional 3,802 shares during the period. Finally, BIT Capital GmbH purchased a new position in Immunome during the 3rd quarter valued at about $69,000. 44.58% of the stock is owned by institutional investors.

Key Immunome News

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: HC Wainwright raised multiple 2026 quarterly EPS forecasts (Q1: from ($0.68) to ($0.53); Q2: ($0.70) to ($0.55); Q3: ($0.72) to ($0.56); Q4: ($0.68) to ($0.58)) and lifted FY2026 estimate to ($2.21) from ($2.78). These narrower loss projections suggest better near‑term operating performance. Article Link
• Positive Sentiment: HC Wainwright also boosted FY2027 (from ($2.20) to ($1.81)) and FY2028 (from ($0.79) to ($0.54)) estimates, implying a faster path toward profitability than previously modeled — a material positive for valuation assumptions. Article Link
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $40 price target while raising FY2029 and FY2030 profit forecasts (FY2029: $0.69 from $0.63; FY2030: $1.35 from $1.28), reinforcing a bullish long‑term view that likely helped buying interest. Article Link
• Neutral Sentiment: Despite the upgrades, HC Wainwright still models losses through FY2028 (FY2026 consensus remains around ($2.21)), so the company is viewed as a longer‑duration growth/turnaround investment rather than near‑term profitable. Article Link

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.